Compare STXS & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STXS | CNTN |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.7M | 185.3M |
| IPO Year | 2004 | 2022 |
| Metric | STXS | CNTN |
|---|---|---|
| Price | $1.62 | $2.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 382.4K | ★ 1.2M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,346,617.00 | N/A |
| Revenue This Year | $28.22 | N/A |
| Revenue Next Year | $30.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.61 | $2.14 |
| 52 Week High | $3.59 | $5.27 |
| Indicator | STXS | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 34.40 | 42.09 |
| Support Level | N/A | $2.14 |
| Resistance Level | $1.99 | $3.80 |
| Average True Range (ATR) | 0.10 | 0.35 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 3.95 | 33.65 |
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.